Corvus Pharmaceuticals Says FDA Granted Orphan Drug Designation For Soquelitinib For Treatment Of T Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Corvus Pharmaceuticals announced that the FDA has granted Orphan Drug Designation to Soquelitinib for the treatment of T Cell Lymphoma. Soquelitinib, the company's lead ITK inhibitor candidate, is slated to enter a Phase 3 clinical trial for relapsed peripheral T cell lymphoma (PTCL) in Q2 2024.
February 08, 2024 | 9:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corvus Pharmaceuticals' Soquelitinib received Orphan Drug Designation from the FDA for T Cell Lymphoma treatment, with a Phase 3 trial expected in Q2 2024.
The FDA's Orphan Drug Designation is a significant regulatory milestone that can enhance the drug's development process and market exclusivity upon approval. This designation, coupled with the advancement to a Phase 3 trial, is likely to be viewed positively by investors, potentially leading to an increase in Corvus Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100